P/E ratio for Anixa Biosciences (ANIX)
P/E ratio as of May 2024 (TTM): -8.49
According to Anixa Biosciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.48571. At the end of 2022 the company had a P/E ratio of -9.24.
P/E ratio history for Anixa Biosciences from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -9.24 | 36.88% |
| 2021 | -6.75 | -1.06% |
| 2020 | -6.82 | 22.72% |
| 2019 | -5.56 | 10.06% |
| 2018 | -5.05 | 32.7% |
| 2017 | -3.81 | -60.26% |
| 2016 | -9.58 | -53.67% |
| 2015 | -20.7 | 789.32% |
| 2014 | -2.32 | -55.47% |
| 2013 | -5.22 | -38.61% |
| 2012 | -8.50 | 181.35% |
| 2011 | -3.02 | -60.71% |
| 2010 | -7.69 | 31.25% |
| 2009 | -5.86 | -37.98% |
| 2008 | -9.45 | -70.34% |
| 2007 | -31.9 | 139.18% |
| 2006 | -13.3 | -38.61% |
| 2005 | -21.7 | -7.06% |
| 2004 | -23.3 | 84.78% |
| 2003 | -12.6 | 202.63% |
| 2002 | -4.18 | -46.98% |
| 2001 | -7.87 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -4.37 | -48.54% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.